Preview

Артериальная гипертензия

Расширенный поиск

Выбор сахароснижающих препаратов у больных сахарным диабетом 2‑го типа очень высокого сердечно-сосудистого риска (часть 2)

https://doi.org/10.18705/1607-419X-2016-22-5-441-455

Полный текст:

Аннотация

Во второй части обзора у больных сахарным диабетом 2‑го типа очень высокого сердечно-сосудистого риска представлены особенности выбора и назначения сахароснижающей терапии из групп тиазолидиндионов, ингибиторов дипептидилпептидазы‑4, агонистов рецепторов и аналогов глюкагонподобного пептида (ГПП) 1‑го типа, селективных ингибиторов натрий-глюкозного котранспортера 2‑го типа. Оценка клинических исследований, метаанализов опубликованных исследований по кардиоваскулярной безопасности сахароснижающих препаратов показала, что наряду с метформином, препаратами первой линии в лечении больных очень высокого сердечно-сосудистого риска, как в монотерапии, так и в комбинации, являются селективные ингибиторы натрий- глюкозного котранспортера 2‑го типа (эмпаглифлозин) и аналоги ГПП 1‑го типа (лираглютид) как лекарственные средства, которые снижают риск развития сердечно-сосудистых событий. Кардиоваскулярная безопасность доказана для агонистов рецепторов ГПП 1‑го типа (ликсисенатид), иДПП‑4 (алоглиптин). При использовании саксаглиптина и ситаглиптина, по данным метаанализов, выявлено увеличение риска сердечной недостаточности. Препараты тиазолидиндионы не рекомендуются для лечения больных сахарным диабетом 2‑го типа очень высокого сердечно-сосудистого риска, особенно при наличии признаков хронической сердечной недостаточности или высокого риска ее развития. С учетом данных первой части статьи в обзоре представлен проект алгоритма выбора инициирующей сахароснижающей терапии у больных очень высокого сердечно-сосудистого риска в зависимости от исходного уровня гликированного гемоглобина.

Об авторах

Н. А. Козиолова
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Министерства здравоохранения Российской Федерации, Пермь, Россия ул. Петропавловская, д. 26, Пермь, Россия, 614000
Россия

доктор медицинских наук, профессор, заведующая кафедрой пропедевтики внутренних болезней № 2 ФГБОУ ВО ПГМУ им. акад. Е. А. Вагнера Минздрава России Факс: +7(342)222–71–13



А. И. Чернявина
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Министерства здравоохранения Российской Федерации, Пермь, Россия
Россия

кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней № 2 ФГБОУ ВО ПГМУ им. акад. Е. А. Вагнера Минздрава России



Е. А. Полянская
Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Министерства здравоохранения Российской Федерации, Пермь, Россия
Россия

кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней № 2 ФГБОУ ВО ПГМУ им. акад. Е. А. Вагнера Минздрава России



Список литературы

1. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD — summary. Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Diab Vasc Dis Res. 2014;11(3):133–73. doi: 10.1177/1479164114525548

2. Дедов И. И., Шестакова М. В., Галстян Г. Р., Григорян О. Р., Есаян М. Р., Калашников В. Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / под ред. И. И. Дедова, М. В. Шестаковой. Сахарный диабет. 2015;18(1S):1–112. [Dedov II, Shestakova MV, Galstyan GR, Grigoryan OR, Esayan MR, Kalashnikov VY et al. Algorithms for specialized medical care for patients with diabetes mellitus. Eds. II Dedov, MV Shestakova. Saharniyi Diabet = Diabetes Mellitus. 2015;18(1S):1–112. In Russian].

3. Gruneir A, Markle-Reid M, Fisher K, Reimer H, Ma X, Ploeg J et al. Comorbidity Burden and Health Services Use in Community-Living Older Adults with Diabetes Mellitus: A Retrospective Cohort Study. Can J Diabetes. 2016;40(1):35–42. doi: 10.1016/j.jcjd.2015.09.002

4. Gao N, Yuan Z, Tang X, Zhou X, Zhao M, Liu L et al. Prevalence of CHD-related metabolic comorbidity of diabetes mellitus in Northern Chinese adults: the REACTION study. J Diabetes Complications. 2016;30(2):199–205. doi: 10.1016/j.jdiacomp.2015.11.018

5. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. doi: 10.1093/eurheartj/ehw106

6. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3–46. PMID:21882396

7. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012;4:4–53. [Diagnosis and correction of lipid metabolism, with a view to the prevention and treatment of atherosclerosis. Russian recommendations. (V) revision. Ateroskleros i Dislipidemiyi = Atherosclerosis and Dyslipidemia. 2012;4:4–53. In Russian].

8. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. doi: 10.1016/j.jacc.2013.11.002

9. Козиолова Н. А., Чернявина А. И., Полянская Е. А. Выбор сахароснижающих препаратов у больных сахарным диабетом 2‑го типа очень высокого сердечно-сосудистого риска (часть 1). Артериальная гипертензия. 2016;22(4):330–348. [Koziolova NA, Chernyavina AI, Polyanskaya EA. Selection of antihyperglycemic agents in high-risk patients with type 2 diabetes mellitus (part 1). Arterial’naya Gipertenziya = Arterial Hypertension. 2016;22(4):330–348. In Russian].

10. Nesto RW, Bell D, Bonow RO, Fonseca V, Fonseca V, Grundy SM et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941–8. doi: 10.1161/01.CIR.0000103683.99399.7E

11. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med. 2001;134(1):61–71. PMID:11187421

12. Khan MA, St Peter JV, Xue JL. A prospective, randomizedcomparison of the metabolic effects -of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2003;25(4):708–11. PMID:11919129

13. Horita S, Nakamura M, Satoh N, Suzuki M, Seki G. Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention. PPAR Res. 2015;2015:646423. doi: 10.1155/2015/646423

14. Rudnicki M, Tripodi GL, Ferrer R, Boscá L, Pitta MG, Pitta IR et al. New thiazolidinediones affect endothelial cell activation and angiogenesis. Eur J Pharmacol. 2016;782:98–106. doi: 10.1016/j.ejphar.2016.04.038

15. Roughead EE, Chan EW, Choi NK, Kimura M, Kimura T, Kubota K et al. Variation in association between thiazolidinediones and heart failure across ethnic groups: retrospective analysis of large healthcare claims databases in six countries. Drug Saf. 2015;38 (9):823–31. doi: 10.1007/s40264– 015–0318–4

16. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279–89. doi:10.1016/S0140–6736(05)67528–9

17. Inzucchi SE, Viscoli CM, Young LH, Inzucchi SE, Viscoli CM, Young LH et al. Pioglitazone prevents diabetes in insulin-resistant patients with cerebrovascular disease. Diabetes Care. 2016. 9(10):1684–92. pii: dc160798. doi:10.2337/dc16–0798

18. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. J Am Med Assoc. 2007;298(10):1180–8. doi:10.1001/jama.298.10.1180

19. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71. doi:10.1056/NEJMoa072761

20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–71. doi:10.1056/NEJMoa072761

21. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP et al. Rosiglitazone evaluated for cardiovascular outcomes an interim analysis.N Engl J Med. 2007;357(1): 28–38. doi:10.1056/NEJMoa073394

22. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. J Am Med Assoc. 2007;298 (10):1189–95. doi:10.1001/jama.298.10.1189

23. [Electronic resource]. URL: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm242588.htm

24. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber A et al. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2013;128(8):785–94. doi: 10.1161/CIRCULATIONAHA.112.000678

25. Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166(2):240–249. doi: 10.1016/j.ahj.2013.05.004

26. [Electronic resource]. URL: http://www.fda.gov/Drugs/DrugSafety/ucm376389.htm

27. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care. Br Med J. 2016;354: i3477. doi: 10.1136/bmj.i3477

28. Erdmann E, Harding S, Lam H, Perez A. Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes. Diabetes Obes Metab. 2016;18(3):266–73. doi: 10.1111/dom.12608

29. Khodeer DM, Zaitone SA, Farag NE, Moustafa YM. Cardioprotective effect of pioglitazone in diabetic and non-diabetic rats subjected to acute myocardial infarction involves suppression of AGE-RAGE axis and inhibition of apoptosis. Can J Physiol Pharmacol. 2016;94(5):463–76. doi: 10.1139/cjpp‑2015–0135

30. Wei WY, Ma ZG, Xu SC, Zhang N, Tang QZ. Pioglitazone Protected against Cardiac Hypertrophy via Inhibiting AKT/GSK3β and MAPK Signaling Pathways. PPAR Res. 2016;2016:9174190. doi: 10.1155/2016/9174190

31. Мареев В. Ю., Агеев Ф. Т., Арутюнов Г. П., Коротеев А. В., Мареев Ю. В., Овчинников А. Г. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Сердечная недостаточность. 2013;14 (7):379–472. [Mareev VY, Ageev FT, Arutyunov GP, Koroteev AV, Mareev YV, Ovchinnikov AG. National recommendations OSSN, RSC and RNMOT for the diagnosis and treatment of heart failure (fourth revision). Serdechnaya Nedostatochnosty = Heart Failure. 2013;14(7):379–472. In Russian].

32. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. doi: 10.1093/eurheartj/ehw128

33. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM et al. 2016 ACC/AHA/HFSA Focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476–88. pii: S0735–1097(16)33024–8. doi: 10.1016/j.jacc.2016.05.011

34. [Electronic resource]. URL: http://www.vidal.ru/drugs/avandia__3575

35. [Electronic resource]. URL: http://www.vidal.kz/poisk_preparatov/actos.htm

36. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase‑4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta- analysis. Br Med J. 2012;344: e1369. doi: 10.1136/bmj.e1369

37. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2‑drug combinations. Ann Intern Med. 2011;154(9):602–13. doi: 10.7326/0003–4819–154–9-201105030–00336

38. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J. 2011;58(1):69–73. PMID: 21206136

39. Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16–27. doi: 10.3810/pgm.2010.05.2138

40. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3. doi: 10.1186/1475–2840– 11–3

41. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3. doi: 10.1186/1475–2840–12–3

42. Iqbal N, Parker A, Frederich R, Donovan M, Hirshberg B. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33. doi: 10.1186/1475–2840–13–33

43. Keating GM. Alogliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2015;75(7):777–96. doi: 10.1007/s40265–015–0385‑y

44. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. doi: 10.1056/NEJMoa1305889

45. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385 (9982):2067–76. doi: 10.1016/S0140– 6736 (14)62225‑X

46. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369 (14):1317–26. doi: 10.1056/NEJMoa1307684

47. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579–88. doi: 10.1161/CIRCULATIONAHA.114.010389

48. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. doi: 10.1056/NEJMoa1501352

49. Weir DL, McAlister FA, Senthilselvan A, Minhas-Sandhu JK, Eurich DT. Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–82. doi: 10.1016/j.jchf.2014.04.005

50. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase‑4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24 (7):689–97. doi: 10.1016/j.numecd.2014.01.017

51. Marney A, Kunchakarra S, Byrne L, Brown N. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. J Hypertension. 2010;56(4):728–33. doi: 10.1161/ HYPERTENSIONAHA.110.156554

52. Desouza CV, Gupta N, Patel A. Cardiometabolic effects of a new class of antidiabetic agents. Clin Ther. 2015;37(6):1178–94. doi: 10.1016/j.clinthera.2015.02.016

53. [Electronic resource]. URL: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494252.htm

54. Raschi E, Poluzzi E, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Dipeptidyl peptidase‑4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Nutr Metab Cardiovasc Dis. 2016;26 (5):380–6. doi: 10.1016/j.numecd.2016.02.006

55. Fava S. Glucagon-like peptide 1 and the cardiovascular system. Curr Diabetes Rev. 2014;10(5):302–10. PMID:25360712

56. Katout M, Zhu H, Rutsky J, Shah P, Shah P, Brook RD et al. Effect of GLP‑1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic metaanalysis and meta-regression. Am J Hypertens. 2014;27(1):130–9. doi: 10.1093/ajh/hpt196

57. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP‑1) receptor agonist exenatide twice daily or other glucoselowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care. 2011;34(1):90–5. doi: 10.2337/dc10– 1393

58. Monami M, Cremasco F, Lamanna C, Colombi C, Desideri CM, Iacomelli I et al. Glucagon-like peptide‑1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764. doi: 10.1155/2011/215764

59. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide‑1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):38–47. doi: 10.1111/dom.12175

60. Wu S, Sun F, Zhang Y, Yang Z, Hong T, Chen Y et al. The cardiovascular effects of glucagon-like peptide‑1 receptor agonists: a trial sequential analysis of randomized controlled trials. J Clin Pharm Ther. 2014;39(1):7–13. doi: 10.1111/jcpt.12102

61. Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3 (9):697–703. doi: 10.1016/S2213–8587(15)00233–8

62. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373 (23):2247–57. doi: 10.1056/NEJMoa1509225

63. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. doi: 10.1056/NEJMoa1603827

64. Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO et al. Glucagon-like peptide‑1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord. 2016;16:91. doi: 10.1186/s12872–016–0260–0

65. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al. Recombinant glucagon-like peptide‑1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955–61. doi:10.1161/01.CIR.0000139339.85840.DD

66. Ravassa S, Zudaire A, Díez J. GLP‑1 and cardioprotection: from bench to bedside. Cardiovasc Res. 2012;94(2):316–23. doi: 10.1093/cvr/cvs123

67. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–50. doi: 10.1161/CIRCULATIONAHA.107.739938

68. Yu M, Moreno C, Hoagland KM, Dahly A, Dahly A, Ditter K et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21(6):1125–35. doi:10.1097/01.hjh.0000059046.65882.49

69. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L et al. Impact of GLP‑1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26–37. doi: 10.1016/j.diabres.2015.07.015

70. Sun F, Wu S, Wang J, Guo S, Chai S, Yang Z et al. Effect of glucagon-like peptide‑1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network metaanalysis. Clin Ther. 2015;37(1):225–241.e8. doi: 10.1016/j.clinthera.2014.11.008

71. [Electronic resource]. URL: https://clinicaltrials.gov

72. Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815–23. doi: 10.2337/dc13–3055

73. Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38 (3):420–8. doi: 10.2337/dc14–1096

74. Scheen AJ. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics. Diabetes Metab. 2016; 42(4):224–33. pii: S1262–3636(16)30409– 8. doi: 10.1016/j.diabet.2016.05.006

75. Dziuba J, Alperin P, Racketa J, Iloeje U, Goswami D, Hardy E et al. Modeling effects of SGLT‑2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab. 2014;16(7):628–35. doi: 10.1111/dom.12261

76. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. doi: 10.1056/NEJMoa1504720

77. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundström J et al. Effects of sodium-glucose cotransporter‑2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4(5):411–9. doi: 10.1016/S2213–8587 (16)00052–8

78. Savarese G, D’Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter‑2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int J Cardiol. 2016;220:595–601. doi: 10.1016/j.ijcard.2016.06.208

79. Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016;37 (19):1526–34. doi: 10.1093/eurheartj/ehv728

80. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375 (4):323–34. doi: 10.1056/NEJMoa1515920

81. Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39 Suppl 2: S165–71. doi: 10.2337/dcS15–3006


Для цитирования:


Козиолова Н.А., Чернявина А.И., Полянская Е.А. Выбор сахароснижающих препаратов у больных сахарным диабетом 2‑го типа очень высокого сердечно-сосудистого риска (часть 2). Артериальная гипертензия. 2016;22(5):441-455. https://doi.org/10.18705/1607-419X-2016-22-5-441-455

For citation:


Koziolova N.A., Chernyavina A.I., Polyanskaya E.A. The choice of antihyperglycemic agents in patients with type 2 diabetes mellitus and very high cardiovascular risk (part 2). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2016;22(5):441-455. (In Russ.) https://doi.org/10.18705/1607-419X-2016-22-5-441-455

Просмотров: 394


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)